Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-053729
Filing Date
2020-11-13
Accepted
2020-11-13 07:30:37
Documents
66
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vcnx-10q_20200930.htm 10-Q 1807688
2 EX-31.1 vcnx-ex311_79.htm EX-31.1 20291
3 EX-31.2 vcnx-ex312_80.htm EX-31.2 20266
4 EX-32.1 vcnx-ex321_81.htm EX-32.1 10945
  Complete submission text file 0001564590-20-053729.txt   5885279

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vcnx-20200930.xml EX-101.INS 1017397
6 XBRL TAXONOMY EXTENSION SCHEMA vcnx-20200930.xsd EX-101.SCH 51805
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vcnx-20200930_cal.xml EX-101.CAL 37163
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vcnx-20200930_def.xml EX-101.DEF 179606
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vcnx-20200930_lab.xml EX-101.LAB 387448
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vcnx-20200930_pre.xml EX-101.PRE 312077
Mailing Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620
Business Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620 585-271-2700
VACCINEX, INC. (Filer) CIK: 0001205922 (see all company filings)

EIN.: 161603202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38624 | Film No.: 201309170
SIC: 2834 Pharmaceutical Preparations